CN111713625A - Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof - Google Patents
Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof Download PDFInfo
- Publication number
- CN111713625A CN111713625A CN202010538017.8A CN202010538017A CN111713625A CN 111713625 A CN111713625 A CN 111713625A CN 202010538017 A CN202010538017 A CN 202010538017A CN 111713625 A CN111713625 A CN 111713625A
- Authority
- CN
- China
- Prior art keywords
- parts
- bacillus coagulans
- eczema
- lactobacillus plantarum
- solid beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 43
- 241000193749 Bacillus coagulans Species 0.000 title claims abstract description 41
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 41
- 229940054340 bacillus coagulans Drugs 0.000 title claims abstract description 40
- 239000007787 solid Substances 0.000 title claims abstract description 16
- 235000013361 beverage Nutrition 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 31
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 21
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 21
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 11
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 11
- 229940064064 purslane extract Drugs 0.000 claims abstract description 10
- 229920001202 Inulin Polymers 0.000 claims abstract description 9
- 229940029339 inulin Drugs 0.000 claims abstract description 9
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 9
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 8
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 8
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000004321 preservation Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- -1 purslane extract Polymers 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 abstract description 13
- 230000001154 acute effect Effects 0.000 abstract description 4
- 244000000010 microbial pathogen Species 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 208000038016 acute inflammation Diseases 0.000 abstract description 2
- 230000006022 acute inflammation Effects 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract description 2
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 230000008591 skin barrier function Effects 0.000 abstract description 2
- 230000037067 skin hydration Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 239000013641 positive control Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000034303 cell budding Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000013566 allergen Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000037380 skin damage Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof, and relates to the field of functional foods, wherein the solid beverage comprises the following raw materials in parts by weight: 20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum. The bacillus coagulans BC99 and the lactobacillus plantarum LP90 adopted by the invention have the effects of relieving eczema, inhibiting the growth of pathogenic microorganisms and promoting metabolism, and meanwhile, functional raw materials of oat beta-glucan and purslane extract are added to endow the functional food with better skin barrier maintenance, participation in skin hydration, acute inflammation resistance and excessive acute expression of epidermal mucosa, so that local symptoms of epidemic eczema are relieved.
Description
Technical Field
The invention relates to the field of functional foods, in particular to a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof.
Background
Eczema is one of clinically common allergic and inflammatory skin diseases, and is a common disease and a frequently encountered disease of dermatology. It is seen that at any age, both men and women may develop the disease without sex difference. It is a skin inflammatory reaction with obvious exudation tendency, and the skin lesion is a polymorphic lesion mainly comprising a pimple, has exudation tendency, is recurrent, has overlapped alternation of acute and chronic periods, is accompanied by severe itching, and is better developed in the elbow fossa, fossa, two sides of the neck, the wrist, the back and the like. The incidence rate of eczema is high, and accounts for 15-25% of the outpatient amount of dermatology, wherein the acute eczema accounts for 52.4%. One survey in the united states showed that the prevalence of various forms of eczema in the general population is 18%; various investigations in the uk have shown that eczema patients constitute 17-30% of all skin patients. It has been reported that the prevalence of eczema increases 2-10 fold in the last 30 years.
The causes of the disease are generally related to the allergic constitution with genetic tendency, the allergens often include food (such as milk, eggs, food eaten by mothers, such as seafood, and the like), inhalants such as pollen, fur fibers, chemical volatile substances, and the like, other contact substances (such as strong wind, pollen, catkin, ice cold water, and the like), vaccinations and the like, and the diseases can be caused and aggravated by the allergens, and the skin cuticle is thin in the infant period, the skin capillaries are rich, and the allergens are also the main mechanisms of the allergic reaction which is easy to occur.
Recent studies have shown that eczema can be caused by infection of various microorganisms, and staphylococcus aureus, branchial sympathetic bacteria and the like can be detected at eczema lesions. The main key points of treating eczema are sterilization, itching relieving, inflammation diminishing and moisture retention. At present, the eczema is mainly treated clinically by glucocorticoid preparations, tar preparations, immunomodulators or antibiotic external preparations. However, long-term clinical application of hormones and antibiotics is prone to cause local adverse reactions such as drug resistance, skin atrophy, telangiectasia, pigmentation and the like.
The condensed budding Paulobacter, also called a budding Lactobacillus, belongs to gram-positive bacteria, is facultative anaerobic, can produce lactic acid, can produce bacteriostatic active substances, and can inhibit the growth of certain putrefactive and pathogenic microorganisms. Because it is non-toxic and harmless to human body, and does not change the characteristics of food itself, it can be used in food industry field. Can inhibit intestinal pathogenic bacteria in animal intestinal tract, and can be used in medical health promotion field.
Disclosure of Invention
The invention provides a bacillus coagulans solid beverage with an effect of relieving eczema and a preparation method thereof, and solves the problem that the existing method for treating eczema usually adopts external corticoid drugs, and has obvious side effects.
In order to solve the technical problems, the technical scheme of the invention is as follows:
the bacillus coagulans solid beverage with the effect of relieving eczema comprises the following raw materials in parts by weight:
20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum.
Preferably, the Bacillus coagulans is Bacillus coagulans BC99, the Bacillus coagulans BC99 is named as Bacillus coagulans with the preservation number as follows: CGMCC No. 19487.
Preferably, the Lactobacillus plantarum is Lactobacillus plantarum Lp90, the Lactobacillus plantarum Lp90 is named Lactobacillus plantarum, and the deposit number is: CGMCC No. 10453.
The preparation method of the bacillus coagulans solid beverage with the effect of relieving eczema comprises the steps of weighing oat beta-glucan, inulin, purslane extract, maltodextrin, bacillus coagulans and lactobacillus plantarum in required parts by weight, and uniformly stirring.
By adopting the technical scheme, the bacillus coagulans BC99 and the lactobacillus plantarum LP90 adopted by the invention have the effects of relieving eczema, inhibiting the growth of pathogenic microorganisms and promoting metabolism, and meanwhile, functional raw materials of oat beta-glucan and purslane extract are added to endow the functional food with better skin barrier maintenance, participation in skin hydration, acute inflammation resistance and inhibition of excessive acute expression of epidermal mucosa, so that local symptoms of wet plague are relieved; the invention takes natural substances as sources, can act on human bodies mildly and without irritation after being mixed according to a certain proportion, and has the effects of bacteriostasis, relieving, diminishing inflammation and resisting allergy. The probiotics is used as a health agent, the existing medicines are not applicable to partial people without generating side effects, and the wide applicable population of the probiotics is not limited by age, sex and medical history.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
Weighing 24 parts of oat beta-glucan, 11 parts of inulin, 4 parts of purslane extract, 32 parts of maltodextrin, 994 parts of bacillus coagulans BC and 902 parts of lactobacillus plantarum Lp, and uniformly stirring.
Bacillus coagulans BC99 deposit unit code: CGMCC-China general microbiological culture Collection center; address: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the detection result of the bacillus coagulans BC99 is as follows: survival; the preservation date is as follows: year 2020, 03, 18 months; the preservation number is: CGMCC No. 19487; and (3) classification and naming: bacillus coagulans Bacillus coagulons.
Lactobacillus plantarum Lp90 deposit unit code: CGMCC-China general microbiological culture Collection center; address: xilu No.1 Hospital No. 3, Beijing, Chaoyang, North; the detection result of the lactobacillus plantarum Lp90 is as follows: survival; the preservation date is as follows: 27 months 01 in 2015; the preservation number is: CGMCC No. 10453; and (3) classification and naming: lactobacillus plantarum.
Oat beta-glucan is a naturally occurring polysaccharide with 1, 3-glycosyl as the main chain and 1, 6-glycosyl as the side chain, obtained by the method described in patent application No. 201510725996.7, namely, by fermentation and extraction of schizophyllum commune. The proliferation rate of skin cells can be improved, the generation of collagen and elastin is promoted, the damaged skin is helped to be updated and repaired, and the healing of scars is promoted; the skin moisture is kept, the moisture retention and the tightening smoothness of the skin are improved, histamine release and degranulation of mast cells are effectively inhibited, sensitive skin is relieved, and skin inflammation is reduced.
The condensed budding Paulobacter, also called a budding Lactobacillus, belongs to gram-positive bacteria, is facultative anaerobic, can produce lactic acid, can produce bacteriostatic active substances, and can inhibit the growth of certain putrefactive and pathogenic microorganisms. Has no toxicity and harm to human body, does not change the characteristics of food, and can better inhibit pathogenic bacteria in animal intestinal tract.
After being ingested, the inulin promotes the growth of intestinal epithelium to enable columnar cells and goblet cells to grow, the mucus of the goblet cells increases, the integrity of colon and the whole intestinal mucosa is sewed, and DNA of the damaged epithelium is repaired. Can significantly increase the growth of bifidobacteria, inhibit the growth of putrefying bacteria, reduce the generation of toxic products, adsorb and chelate toxic fermentation products, remove putrefying products and bacterial toxins, thereby reducing the burden of the liver and promoting the synthesis of nutrients.
The herba Portulacae extractive solution is prepared by dissolving bioactive substances obtained by low-temperature extraction method in 39.5% butanediol solution, has broad-spectrum antibacterial, antiinflammatory and antiallergic effects, and can promote physiological function recovery of epithelial cells.
Example 2
Weighing 20 parts of oat beta-glucan, 10 parts of inulin, 3 parts of purslane extract, 30 parts of maltodextrin, 993 parts of bacillus coagulans BC and 901 parts of lactobacillus plantarum, and uniformly stirring.
Example 3
Weighing 30 parts of oat beta-glucan, 15 parts of inulin, 5 parts of purslane extract, 35 parts of maltodextrin, 995 parts of bacillus coagulans BC and 905 parts of lactobacillus plantarum, and uniformly stirring.
Example 4
The effect of relieving eczema is carried out animal experiment research
Experimental materials: ICR mice 72, 18-22 g.
The experimental process comprises the following steps: the 72 mice were randomly divided into 6 groups of 12 mice each, which served as a blank group, a model group, bacillus coagulans functional food high, medium, and low dose groups, and a positive control group, respectively. Removing mouse abdominal hair with electric hair clipper and electric hair cutter, and applying 5% 2, 4-Dinitrochlorobenzene (DNCB)30 μ L to skin for first sensitization of model group, Bacillus coagulans functional food high, medium and low dosage groups and positive control group; on day 5, a second antigen challenge was performed by applying 50. mu.L of 0.2% DNCB to a 2cm by 2cm shaved area of the back, the symmetrical shaved area of the left back being free of drug as a control. After that, the excitation was performed 1 time every 3d for 3 times. On the 9 th day, the right back of the mouse is observed to obviously have erythema, edema, pimple, erosion or exudation compared with the left back, which indicates that the molding is successful.
After 10 days of the experiment, the mice of each group were treated with drugs, and the high, medium and low dose groups of the bacillus coagulans functional food of example 1 were intragastrically filled with 1g, 0.5g and 0.25g of the bacillus coagulans functional food of example 1 dissolved in 2mL of distilled water, respectively, every day, the positive control group was intragastrically filled with 2mL of phellodendron bark solution, and the model group and the blank control group were intragastrically filled with 2mL of distilled water, respectively. The medicine is administered according to group and dosage 3 times a day for 10 days on the day of successful model building.
1. Comparison of degree of swelling of skin on the back and inhibition rate of the mice
After the experiment, the animals were sacrificed, and the skin of the right dermatitis area of the back of the mouse and the symmetrical healthy skin of the left side were cut off respectively without removing adipose tissues using sterile surgical scissors, and the skin of the same area was punched out respectively using a circular punch having a diameter of 6mm, and weighed using an analytical balance. The degree of swelling and inhibition rate of the back skin of the mice in each experimental group are detected.
Group of | Animal number (only) | Swelling degree (mg, x + -SD) | Inhibition ratio (%) |
Blank group | 12 | 6.21 | / |
Model set | 12 | 16.84±2.43 | / |
High dose | 12 | 9.38±1.47* | 70.18±9.63 |
Middle dose | 12 | 12.41±6.47* | 41.67±7.88 |
Low dose | 12 | 14.68±5.15 | 20.32±22.41 |
Positive control | 12 | 7.79±14.26 | 85.14±11.57 |
Note: p <0.05 compared to control group
The results are shown in the table above, which shows that the bacillus coagulans functional food can obviously reduce the swelling degree of the mouse ear caused by 5 percent of 2, 4-dinitrochlorobenzene, and has obvious inhibition effect on swelling inflammation of the mouse ear.
2. Comparison of inflammatory cytokines in eczema lesions in mice
After the test is finished, the skin of the model-making part is taken down from the abdomen of the mouse by adopting a sterile surgical scissors, the tissue is quickly fixed in 4 percent paraformaldehyde liquid immersion, and the expression levels of IFN-gamma Ra, IL-2 and TNF-alpha in the skin tissue of the skin lesion of each experimental group are detected.
Note:#compared with the model group, the model group is compared,*compared with the hormone group, is less than 0.05,##compared with the model group, the model group is compared,**compared with a positive control group, the ratio is less than 0.01。
2.1 comparison of FN-gamma Ra amounts in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups can suppress the reduction of FN-gamma Ra in the eczema wound skin damage of the mice caused by the 2, 4-dinitrochlorobenzene, and the 5 groups have statistically significant difference (P <0.05) compared with the model group. The medium dose group had statistical significance in promoting FN- γ Ra in the skin compared to the positive control group (P < 0.05); the difference between the high dose group and the model group was not statistically significant (P > 0.05)). Due to the dose-effect relationship between the low, medium and high doses, the difference in comparison (P <0.01) between the low, medium and high dose groups was statistically significant. From the X + S values: for improving the improvement of FN-gamma Ra in the skin tissues of the mouse eczema model, the result shows that the overall curative effect of the positive control group is still higher than that of the low, medium and high dose groups; the high dose group has slightly stronger curative effect than the medium dose group, the curative effect is close to that of the control group, and the low dose group has low curative effect.
2.2 comparison of IL-2 levels in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups have obvious effect on reducing IL-2 in the eczema wound skin damage of the mice by using the 2, 4-dinitrochlorobenzene, and the 5 groups have statistically significant difference (P is less than 0.01) compared with the model group. The IL-2 in the medium-dose group is statistically different from that in the western-medicine group in the reduction of the wound skin damage (P < 0.05); the low, medium and high doses have dose-effect relationship, and the difference of the low dose group, the medium dose group and the high dose group (P <0.01) has obvious statistical significance. From the X + S values: for the improvement of IL-2 in the skin tissue of the mouse eczema model, the result shows that the overall efficacy of the positive control group is higher than that of the high-dose group; the middle dose group was slightly less effective than the high dose group, with the low dose group having the lowest efficacy.
2.3 comparison of TNF-alpha amounts in eczema lesions in mice
From the experimental results shown in the table above, it can be seen that: the high-dose, medium-dose, low-dose and positive control groups have obvious effect on reducing TNF-alpha in the eczema wound skin lesion of the mouse by using 2, 4-dinitrochlorobenzene, and the 5 groups have obvious difference (P is less than 0.01) in the phylogenetic aspect after being compared with the model group. The high dose group was statistically significant in reducing TNF- α in the skin compared to the difference between the hormone groups (P < 0.05); because of the dose-effect relationship between the low, medium and high doses, the difference of the low, medium and high dose groups (P <0.01) is statistically significant. From the X + S values: for the improvement of reducing TNF-alpha in the skin tissue of the mouse eczema model, the result shows that the whole curative effect of the positive control group is still higher than that of the dose group; the middle dose group was slightly less effective than the high dose group, with the low dose group having the lowest efficacy.
In conclusion, the bacillus coagulans functional food shows anti-inflammatory inhibition effect on 2, 4-dinitrochlorobenzene-induced auricular edema, inflammation and other chronic inflammation models, wherein the anti-inflammatory, skin-moistening and anti-allergy effects are better in high-concentration effect and slightly better than medium-concentration effect.
After the mouse takes the composition, the effective components in the composition can be absorbed by human body to indirectly improve the generation of IL-2 and FN-gamma Ra of skin lesions of the mouse with eczema, thereby effectively reducing the bovine cost of TNF-alpha and being beneficial to the repair and recovery of the skin lesions of the eczema. The experimental results show that: the high-concentration solid beverage has good curative effect; wherein the effects of the low and medium concentration solid beverages are similar, and the positive control group has stronger effects on improving FN-gamma Ra and IL-2 in skin lesions of the eczema mice and indirectly reducing the generation of TNF-alpha than the different gradient dose groups.
Although the results of statistical analysis and experiments show that each index of the hormone group is obviously superior to that of each dosage group, the frequency, times, recurrence rate, hormone side effect and the like of taking are considered in the long term, and the probiotic solid preparation has the advantages of safety and less toxic and side effects compared with other hormone medicines based on the consideration, and has better clinical curative effect, simplicity and convenience.
3. Comparison of degree of liver injury in mice of each experimental group
Blood is taken from retrobulbar venous plexus to measure serum ALT, meanwhile, cervical vertebra is pulled off to kill mice and take liver, liver homogenate is prepared, supernatant is taken to measure liver TG, the ALT and TG value changes of the mice of each group are compared, and the influence of bacillus coagulans functional food on the liver of the mice is verified.
Group of | Animal number (only) | ALT/U·L-1 | TG/mg·Kg-1liver |
Blank group | 12 | 122.66±13.79 | 14.9±1.0 |
Model set | 12 | 121.21±12.54 | 14.7±1.9 |
High dose | 12 | 127.87±9.62 | 15.5±2.0 |
Middle dose | 12 | 124.58±6.97 | 15.2±2.7 |
Low dose | 12 | 124.24±16.78 | 15.0±1.8 |
The results in the table show that compared with the normal control group mice, the ALTT and TG values of the bacillus coagulans functional food high and medium dosage group in the example 1 have no significant difference, and the functional food has no obvious damage to the liver and can be used for adjuvant therapy of eczema.
The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (4)
1. A bacillus coagulans solid beverage with an effect of relieving eczema is characterized in that: the feed comprises the following raw materials in parts by weight:
20-30 parts of oat beta-glucan, 10-15 parts of inulin, 3-5 parts of purslane extract, 30-35 parts of maltodextrin, 3-5 parts of bacillus coagulans and 1-5 parts of lactobacillus plantarum.
2. The bacillus coagulans solid beverage with the efficacy of relieving eczema as claimed in claim 1, wherein: the Bacillus coagulans is Bacillus coagulans BC99, the Bacillus coagulans BC99 is named as Bacillus coagulans, and the preservation number is as follows: CGMCC No. 19487.
3. The bacillus coagulans solid beverage with the efficacy of relieving eczema as claimed in claim 1, wherein: the lactobacillus plantarum is lactobacillus plantarum Lp90, the lactobacillus plantarum Lp90 is named lactobacillus plantarum, and the preservation number is as follows: CGMCC No. 10453.
4. A method for preparing a bacillus coagulans solid beverage with an eczema relieving effect according to any one of claims 1 to 3, wherein the bacillus coagulans solid beverage is prepared by the following steps: weighing oat beta-glucan, inulin, purslane extract, maltodextrin, bacillus coagulans and lactobacillus plantarum in required weight parts, and uniformly stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010538017.8A CN111713625A (en) | 2020-06-12 | 2020-06-12 | Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010538017.8A CN111713625A (en) | 2020-06-12 | 2020-06-12 | Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111713625A true CN111713625A (en) | 2020-09-29 |
Family
ID=72566625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010538017.8A Pending CN111713625A (en) | 2020-06-12 | 2020-06-12 | Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111713625A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112425776A (en) * | 2020-12-11 | 2021-03-02 | 安徽国膳生物科技有限公司 | Medicated diet for people with eczema |
CN115607577A (en) * | 2022-10-09 | 2023-01-17 | 微康益生菌(苏州)股份有限公司 | Probiotic with effect of relieving stomatitis as well as preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839681A (en) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people with damp heat constitution |
CN106075120A (en) * | 2016-07-01 | 2016-11-09 | 宁波希诺亚海洋生物科技有限公司 | A kind of Eczema Creams agent |
CN107212378A (en) * | 2016-03-22 | 2017-09-29 | 内蒙古伊利实业集团股份有限公司 | A kind of function composition with regulation enteron aisle and its application |
CN108850774A (en) * | 2018-07-04 | 2018-11-23 | 于银行 | One compound health-preserving beverage of seed ginseng Rui and preparation method thereof |
CN108991327A (en) * | 2018-07-24 | 2018-12-14 | 北京奥维森基因健康科技有限公司 | A kind of probiotics solid beverage and preparation method thereof |
-
2020
- 2020-06-12 CN CN202010538017.8A patent/CN111713625A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104839681A (en) * | 2015-04-14 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people with damp heat constitution |
CN107212378A (en) * | 2016-03-22 | 2017-09-29 | 内蒙古伊利实业集团股份有限公司 | A kind of function composition with regulation enteron aisle and its application |
CN106075120A (en) * | 2016-07-01 | 2016-11-09 | 宁波希诺亚海洋生物科技有限公司 | A kind of Eczema Creams agent |
CN108850774A (en) * | 2018-07-04 | 2018-11-23 | 于银行 | One compound health-preserving beverage of seed ginseng Rui and preparation method thereof |
CN108991327A (en) * | 2018-07-24 | 2018-12-14 | 北京奥维森基因健康科技有限公司 | A kind of probiotics solid beverage and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
涂艳华等: "新型益生菌凝结芽孢杆菌BC99在食品中的应用", 《食品工业科技》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112425776A (en) * | 2020-12-11 | 2021-03-02 | 安徽国膳生物科技有限公司 | Medicated diet for people with eczema |
CN115607577A (en) * | 2022-10-09 | 2023-01-17 | 微康益生菌(苏州)股份有限公司 | Probiotic with effect of relieving stomatitis as well as preparation method and application thereof |
CN115607577B (en) * | 2022-10-09 | 2024-01-30 | 微康益生菌(苏州)股份有限公司 | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI607758B (en) | Lactobacillus paracasei strain gmnl-653 and composition having the same for improving psoriasis symptoms | |
CN115607577B (en) | Probiotics with efficacy of relieving stomatitis, and preparation method and application thereof | |
KR101734960B1 (en) | Leuconostoc holzapfelii stain for preventing depilation, improving hair growth or improving sexual disfunction, and composition comprising the same | |
CN109985069B (en) | Probiotic compositions and uses thereof | |
CN111713625A (en) | Bacillus coagulans solid beverage with efficacy of relieving eczema and preparation method thereof | |
CN112999261A (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
KR100871837B1 (en) | Bacterial Culture Having Effects of Suppressing Dermatitis Development and Accelerating Skin Wound Healing, and Product Using The Same | |
CN111297961A (en) | Dong medicine for promoting wound healing | |
CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
CN113633702A (en) | Dai medicine composition for relieving senile cutaneous pruritus and preparation and application thereof | |
US11826380B2 (en) | Application of low-molecular-weight hyaluronic acid (LMW-HA) fragments | |
CN107468999A (en) | A kind of fermentation composition with beauty treatment and eliminating spot function and preparation method thereof | |
CN113995775A (en) | Probiotic foot mask with foot protection effect and preparation method thereof | |
CN112057601A (en) | Preparation method of active probiotic freeze-dried powder and application of active probiotic freeze-dried powder in skin and gynecological diseases | |
Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
US20060127518A1 (en) | Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion | |
RU2484669C1 (en) | Method of correcting vaginal dysbiosis in case of metabolic syndrome | |
CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
CN114767708B (en) | Stable gynecological antibacterial composition and gynecological care solution | |
CN105168638A (en) | Traditional Chinese medicinal liquid band aid for preventing and treating bedsore complicated with bacterial infection | |
CN105106475A (en) | Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing | |
CN104491554B (en) | A kind of medicine for treating mastitis and preparation method thereof | |
CN115844993A (en) | A Chinese medicinal disinfectant for oral cavity and skin, and its preparation method | |
CN118615354A (en) | Application of citron or extract thereof in preparation of medicines for treating ulcerative colitis and pharmaceutical composition for treating ulcerative colitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200929 |